This award recognises Abcam as the antibody company which has seen sustained success in the Chinese market over the past five years.

From the data generated through CiteAb we are able to gain a really clear picture of the way antibodies are used around the world. We can tell which countries are investing most in research using antibodies, which companies are seeing growth or decline, which antibodies are most successful and which areas of research are seeing growth.

Dr Andrew Chalmers, Founder of CiteAb, said: “The winner for this award, Abcam, was determined based on CiteAb citation data over a five year period from 2013 – 2017. The company has done extremely well over the past year in multiple markets, and has clearly seen a great deal of success. With China being such an essential region to crack, its great to see that Abcam has managed to do so!”